Antiretroviral drug

Results: 3075



#Item
51ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P

ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2015-01-27 14:49:56
52KY HIV Test Form Template.pub

KY HIV Test Form Template.pub

Add to Reading List

Source URL: www.chfs.ky.gov

Language: English - Date: 2015-06-08 14:24:25
53KWP BRIEFING SHEET 2  HIV AND IMMIGRATION The knowledge, the will and the power (KWP) states the National African HIV Prevention Programme’s (NAHIP) plan to prevent sexual HIV transmissions among African people in Engl

KWP BRIEFING SHEET 2 HIV AND IMMIGRATION The knowledge, the will and the power (KWP) states the National African HIV Prevention Programme’s (NAHIP) plan to prevent sexual HIV transmissions among African people in Engl

Add to Reading List

Source URL: kwp.org.uk

Language: English - Date: 2012-10-19 08:13:55
54DEPARTMENT OF HEALTH & HUMAN SERVICES  Health Resources and Services Administration  –––––––––––––––––––––––––––––––––––––––––––––

DEPARTMENT OF HEALTH & HUMAN SERVICES Health Resources and Services Administration –––––––––––––––––––––––––––––––––––––––––––––

Add to Reading List

Source URL: www.hab.hrsa.gov

Language: English
55Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV London, United Kingdom, 11 July 2012: Shionogi-ViiV Healthcare LLC today announced that initia

Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV London, United Kingdom, 11 July 2012: Shionogi-ViiV Healthcare LLC today announced that initia

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:18
56Open Invitation to Join Session 11 of PH 236: US Food and Drug Administration, Drug Development, Science and Health Policy Session 11: Response to Global HIV and HCV Epidemics April 9, 2015 * Stanley Hall 105 * 6:30-8:30

Open Invitation to Join Session 11 of PH 236: US Food and Drug Administration, Drug Development, Science and Health Policy Session 11: Response to Global HIV and HCV Epidemics April 9, 2015 * Stanley Hall 105 * 6:30-8:30

Add to Reading List

Source URL: www.hivforum.org

Language: English - Date: 2015-03-26 14:39:35
57Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir compared to raltegravir over 48 weeks in treatm

Shionogi-ViiV Healthcare Announces Initial Data from Pivotal Phase III Study of Dolutegravir in HIV SPRING-2 study meets primary endpoint of non-inferiority of dolutegravir compared to raltegravir over 48 weeks in treatm

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:24
58Int. J. BiosciInternational Journal of Biosciences (IJB) ISSN: PrintOnline) Vol. 2, No. 7, p, 2012

Int. J. BiosciInternational Journal of Biosciences (IJB) ISSN: PrintOnline) Vol. 2, No. 7, p, 2012

Add to Reading List

Source URL: www.innspub.net

Language: English - Date: 2012-07-22 10:37:45
59EMAIL YOUR QUESTIONS TO  www.projectinform.org/questions JANUARY 2011

EMAIL YOUR QUESTIONS TO www.projectinform.org/questions JANUARY 2011

Add to Reading List

Source URL: www.projectinform.org

Language: English - Date: 2011-06-27 20:05:23
60Interventions to Increase Cervical Cancer Screening Rates

Interventions to Increase Cervical Cancer Screening Rates

Add to Reading List

Source URL: www.aafp.org

Language: English - Date: 2014-02-20 15:40:26